news
AbbVie and Boehringer Ingelheim collaborate on BI 655066
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
List view / Grid view
Asthma
news
Roche provides update on two Phase III studies of lebrikizumab in asthma
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...
news
Boehringer Ingelheim’s Spiriva Respimat available in the US
4 February 2016 | By Victoria White
Unlike other asthma daily maintenance treatments, Spiriva Respimat is from a new class of medications in asthma known as long-acting anticholinergics...
news
Do asthma and COPD exist? Experts call for a new approach to patient management
1 February 2016 | By Victoria White
Defining a patient’s symptoms using the historical diagnostic labels of asthma and COPD is an outdated approach, according to experts...
news
CHMP recommends mepolizumab for severe refractory eosinophilic asthma
24 September 2015 | By Victoria White
Mepolizumab is an anti-IL 5 monoclonal antibody that is delivered in a 100mg dose via subcutaneous injection every four weeks...
news
FDA approves asthma treatment Spiriva Respimat
16 September 2015 | By Victoria White
It is approved by the FDA for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older...
news
Teva files MAA for asthma treatment reslizumab
28 July 2015 | By Victoria White
Teva has successfully filed a MAA with the EMA for reslizumab -a humanised anti-IL-5 monoclonal antibody for the treatment of inadequately controlled asthma...
news
FDA accepts Teva’s Biological License Application for reslizumab for review
15 June 2015 | By
The US Food and Drug Administration (FDA) has accepted for review Teva’s Biologics License Application (BLA) for reslizumab...
news
Mylan launches Sirdupla in the UK for adult sufferers of asthma
8 June 2015 | By Victoria White
Mylan has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide Evohaler under the brand name Sirdupla in the UK...
news
Regeneron and Sanofi announce positive Phase 2b dupilumab data in asthma
19 May 2015 | By Victoria White
Regeneron and Sanofi have shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA).
news
New Phase III data presented for first time demonstrate tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
